Waverley Pharma Inc.WAVE.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · waverleypharma.com
Canadian biopharmaceutical company focused on research, development, and commercialization of oncology therapeutics, primarily PARP-1 inhibitors for cancer treatment. Also manages a licensed portfolio of cancer medications including Capecitabine and Temozolomide, with commercial launches in the United Kingdom and Germany. Operates a retail pharmacy in the United States acquired in 2024 to generate near-term revenue.
Key ratios
FCF / Sales
-30.8%TTM
2024
-86.3%2023
-247.8%2022
-19.0%
Net margin
-24.4%TTM
2024
-199.2%2022
-53.3%
ROA
-12.3%TTM
2024
-35.9%2023
-44.1%2022
-18.4%
ROE
-46.1%2022
Revenue growth
2016.3%TTM
2024
15.4%2023
-67.0%2022
-28.9%
Recent news
Track WAVE.V in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer